Reference is made to the stock exchange announcement by Lifecare ASA (the
"Company") on 12 June 2026 regarding the final results following expiry of the
exercise period for the warrants series 2 with ISIN NO0013709204 ("Warrants
Series 2") issued in connection with the partially underwritten rights issue
of new shares in the Company completed in January 2026.
A total of 109,590,722 Warrants Series 2 were exercised at the exercise price
of NOK 0.24899 per share, resulting in gross proceeds of approx. NOK
27,286,994.
The share capital increase pertaining to the issuance of new shares as a
result of the exercised Warrants Series 2 has now been registered with the
Norwegian Register of Business Enterprises. The Company's new share capital is
NOK 40,771,147.10 divided into 407,711,471 shares, each with a nominal value
of NOK 0.10.
The new shares are expected to be delivered to the VPS accounts of the
subscribers to whom they are allocated on or about 26 June 2026, subject to
timely payment having been received.
About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Petter Nielsen, CFO, petter.nielsen@lifecare.no, +47 92 24 74 64
This information is subject to disclosure under the Norwegian Securities
Trading Act, ยง5-12. The information was submitted for publication, through the
agency of the contact persons set out above, at 2026-06-22 13:05 CEST.